Zoledronic acid boosts γδ T-cell activity in children receiving αβ⁺ T and CD19⁺ cell-depleted grafts from an HLA-haplo-identical donor.

ABSTRACT: We demonstrated that γδ T cells of patients given HLA-haploidentical HSCT after removal of αβ⁺ T cells and CD19⁺ B cells are endowed with the capacity of killing leukemia cells after ex vivo treatment with zoledronic acid (ZOL). Thus, we tested the hypothesis that infusion of ZOL in patients receiving this type of graft may enhance γδ T-cell cytotoxic activity against leukemia cells. ZOL was infused every 28 d in 43 patients; most were treated at least twice. γδ T cells before and after ZOL treatments were studied in 33 of these 43 patients, till at least 7 mo after HSCT by high-resolution mass spectrometry, flow-cytometry, and degranulation assay. An induction of Vδ2-cell differentiation, paralleled by increased cytotoxicity of both Vδ1 and Vδ2 cells against p

SUBMITTER: Bertaina A 

PROVIDER: S-EPMC5353934 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature